Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Statement: Penicillin Shortage
Penicillin VK solution is suffering from intermittent supply shortages. This can affect children with sickle cell disease. Penicillin VK in liquid form is prescribed for babies and young children with sickle cell disease who are unable to swallow pills as standard care, twice a day, starting as early as 6-8 weeks of age. Children less than 3 years of age should receive oral penicillin 125 mg twice daily, and the dose should be increased to 250 mg twice daily for children older than 3 years.
+myBinderRelated Content
-
Hydroxyurea for children with sickle cell anemia in Sub-Saharan AfricaBackground: Hydroxyurea is an effective...
-
Timothy Lee McCavit, MDTimothy L. McCavit earned a MS in molecu...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
Children’s Healthcare of Atlanta Sickle Cell Disease ProgramChildren's Healthcare of Atlanta's Sickl...
-
Developing Hydroxyurea, the First FDA-Approved Therapy for Sickle Cell Diseasehttps://www.youtube.com/watch?v=0kIz5ZKy...
-
Dr. Nina AndersonDr. Nina Anderson, completed her doctora...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.